• Je něco špatně v tomto záznamu ?

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease

T. Berger, M. Adamczyk-Sowa, T. Csépány, F. Fazekas, TH. Fabjan, D. Horáková, AH. Ledinek, Z. Illes, G. Kobelt, SŠ. Jazbec, E. Klímová, F. Leutmezer, K. Rejdak, C. Rozsa, J. Sellner, K. Selmaj, P. Štouracˇ, J. Szilasiová, P. Turcˇáni, M. Vachová,...

. 2020 ; 13 (-) : 1756286420975223. [pub] 20201207

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21001596

At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and 2019 factors influencing daily treatment choices in MS, especially practice guidelines, biomarkers and burden of disease, were discussed. The heterogeneity of MS and the complexity of the available treatment options call for informed treatment choices. However, evidence from clinical trials is generally lacking, particularly regarding sequencing, switches and escalation of drugs. Also, there is a need to identify patients who require highly efficacious treatment from the onset of their disease to prevent deterioration. The recently published European Committee for the Treatment and Research in Multiple Sclerosis/European Academy of Neurology clinical practice guidelines on pharmacological management of MS cover aspects such as treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and are based on expert consensus statements. However, the recommendations constitute an excellent framework that should be adapted to local regulations, MS center capacities and infrastructure. Further, available and emerging biomarkers for treatment guidance were discussed. Magnetic resonance imaging parameters are deemed most reliable at present, even though complex assessment including clinical evaluation and laboratory parameters besides imaging is necessary in clinical routine. Neurofilament-light chain levels appear to represent the current most promising non-imaging biomarker. Other immunological data, including issues of immunosenescence, will play an increasingly important role for future treatment algorithms. Cognitive impairment has been recognized as a major contribution to MS disease burden. Regular evaluation of cognitive function is recommended in MS patients, although no specific disease-modifying treatment has been defined to date. Finally, systematic documentation of real-life data is recognized as a great opportunity to tackle unresolved daily routine challenges, such as use of sequential therapies, but requires joint efforts across clinics, governments and pharmaceutical companies.

Centrum Teplice Teplice Czech Republic

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Neurology and MTA SZTE Neuroscience Research Group University of Szeged Szeged Hungary

Department of Neurology Comenius University Bratislava Slovakia

Department of Neurology Faculty of Medical Sciences in Zabrze Medical University of Silesia in Katowice Poland

Department of Neurology Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Neurology Jahn Ferenc Dél pesti Hospital Budapest Hungary

Department of Neurology Landesklinikum Mistelbach Gänserndorf Mistelbach Austria and Department of Neurology Christian Doppler Medical Center Paracelsus Medical University Salzburg Austria

Department of Neurology Masaryk University Brno Czech Republic

Department of Neurology Medical University of Graz Graz Austria

Department of Neurology Medical University of Lublin Lublin Poland

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Medical University of Vienna Waehringer Guertel 18 20 Vienna 1090 Austria

Department of Neurology P J Šafárik University Košice and University Hospital of L Pasteur Košice Slovakia

Department of Neurology University Clinical Centre Ljubljana Ljubljana Slovenia

Department of Neurology University Medical Centre Maribor Maribor Slovenia

Department of Neurology University of Prešov and Teaching Hospital of J A Reiman Prešov Slovakia

Department of Neurology University of Southern Denmark Odense Denmark

Department of Neurology University of Warmia Mazury Olsztyn Poland

Department of Radiology MRI Unit 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

European Health Economics AB Stockholm Sweden

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21001596
003      
CZ-PrNML
005      
20210126092843.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1756286420975223 $2 doi
035    __
$a (PubMed)33335562
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Berger, Thomas $u Department of Neurology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.
245    10
$a Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. / $c T. Berger, M. Adamczyk-Sowa, T. Csépány, F. Fazekas, TH. Fabjan, D. Horáková, AH. Ledinek, Z. Illes, G. Kobelt, SŠ. Jazbec, E. Klímová, F. Leutmezer, K. Rejdak, C. Rozsa, J. Sellner, K. Selmaj, P. Štouracˇ, J. Szilasiová, P. Turcˇáni, M. Vachová, M. Vanecková, L. Vécsei, EK. Havrdová,
520    9_
$a At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and 2019 factors influencing daily treatment choices in MS, especially practice guidelines, biomarkers and burden of disease, were discussed. The heterogeneity of MS and the complexity of the available treatment options call for informed treatment choices. However, evidence from clinical trials is generally lacking, particularly regarding sequencing, switches and escalation of drugs. Also, there is a need to identify patients who require highly efficacious treatment from the onset of their disease to prevent deterioration. The recently published European Committee for the Treatment and Research in Multiple Sclerosis/European Academy of Neurology clinical practice guidelines on pharmacological management of MS cover aspects such as treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and are based on expert consensus statements. However, the recommendations constitute an excellent framework that should be adapted to local regulations, MS center capacities and infrastructure. Further, available and emerging biomarkers for treatment guidance were discussed. Magnetic resonance imaging parameters are deemed most reliable at present, even though complex assessment including clinical evaluation and laboratory parameters besides imaging is necessary in clinical routine. Neurofilament-light chain levels appear to represent the current most promising non-imaging biomarker. Other immunological data, including issues of immunosenescence, will play an increasingly important role for future treatment algorithms. Cognitive impairment has been recognized as a major contribution to MS disease burden. Regular evaluation of cognitive function is recommended in MS patients, although no specific disease-modifying treatment has been defined to date. Finally, systematic documentation of real-life data is recognized as a great opportunity to tackle unresolved daily routine challenges, such as use of sequential therapies, but requires joint efforts across clinics, governments and pharmaceutical companies.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Adamczyk-Sowa, Monika $u Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland.
700    1_
$a Csépány, Tünde $u Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
700    1_
$a Fazekas, Franz $u Department of Neurology, Medical University of Graz, Graz, Austria.
700    1_
$a Fabjan, Tanja Hojs $u Department of Neurology, University Medical Centre Maribor, Maribor, Slovenia.
700    1_
$a Horáková, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Ledinek, Alenka Horvat $u Department of Neurology, University Clinical Centre Ljubljana, Ljubljana, Slovenia.
700    1_
$a Illes, Zsolt $u Department of Neurology, University of Southern Denmark, Odense, Denmark.
700    1_
$a Kobelt, Gisela $u European Health Economics AB, Stockholm, Sweden.
700    1_
$a Jazbec, Saša Šega $u Department of Neurology, University Clinical Centre Ljubljana, Ljubljana, Slovenia.
700    1_
$a Klímová, Eleonóra $u Department of Neurology, University of Prešov and Teaching Hospital of J. A. Reiman, Prešov, Slovakia.
700    1_
$a Leutmezer, Fritz $u Department of Neurology, Medical University of Vienna, Vienna, Austria.
700    1_
$a Rejdak, Konrad $u Department of Neurology, Medical University of Lublin, Lublin, Poland.
700    1_
$a Rozsa, Csilla $u Department of Neurology, Jahn Ferenc Dél-pesti Hospital, Budapest, Hungary.
700    1_
$a Sellner, Johann $u Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria, and Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.
700    1_
$a Selmaj, Krzysztof $u Department of Neurology, University of Warmia-Mazury, Olsztyn, Poland.
700    1_
$a Štouracˇ, Pavel $u Department of Neurology, Masaryk University, Brno, Czech Republic.
700    1_
$a Szilasiová, Jarmila $u Department of Neurology, P. J. Šafárik University Košice and University Hospital of L. Pasteur Košice, Slovakia.
700    1_
$a Turcˇáni, Peter $u Department of Neurology, Comenius University, Bratislava, Slovakia.
700    1_
$a Vachová, Marta $u Centrum Teplice, Teplice, Czech Republic.
700    1_
$a Vanecková, Manuela $u Department of Radiology, MRI Unit, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Vécsei, László $u Department of Neurology and MTA-SZTE Neuroscience Research Group, University of Szeged, Szeged, Hungary.
700    1_
$a Havrdová, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
773    0_
$w MED00177176 $t Therapeutic advances in neurological disorders $x 1756-2856 $g Roč. 13, č. - (2020), s. 1756286420975223
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33335562 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092839 $b ABA008
999    __
$a ind $b bmc $g 1613943 $s 1121880
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 13 $c - $d 1756286420975223 $e 20201207 $i 1756-2856 $m Therapeutic advances in neurological disorders $n Ther Adv Neurol Disord $x MED00177176
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace